![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1660953
Ç÷Àü Á¦°Å ±â±â ½ÃÀå º¸°í¼ : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)Thrombectomy Devices Market Report by Product Type, Application, End User, and Region 2025-2033 |
Ç÷Àü Á¦°Å ±â±â ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 14¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 21¾ï 3,000¸¸ ´Þ·¯¿¡ À̸£°í 2025-2033³âÀÇ ¼ºÀå·ü(CAGR)Àº 4.48%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. À̹ÌÁö À¯µµ ¼ö¼úÀ» ¼öÇàÇÏ´Â ¿Ü°ú ÀÇ»çÀÇ Ç÷Àü Á¦°Å ±â±â¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿Í °Ç° °ü¸® ÀÎÇÁ¶óÀÇ Áö¼ÓÀûÀÎ °³¼±ÀÌ ½ÃÀåÀ» ÁÖ·Î °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
Ç÷Àü Á¦°Å ±â±â´Â ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®, °æ»ö Å©±â °¨¼Ò, ST ºÎ¹® ÇØ¼Ò, ½É±Ù °æ»ö¿¡¼ Ç÷°ü Á¶¿µ Ç÷Àü ¿ëÇØ(TIMI) È帧°ú °°Àº ´ëü ¿£µåÆ÷ÀÎÆ®¿¡¼ ¸¹Àº ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ ±â±â´Â ¼ö¼ú Áß ÃâÇ÷°ú Ç÷°ü º® ¼Õ»óÀ» ÃÖ¼ÒÈÇÕ´Ï´Ù. ±× °á°ú Á¤¸Æ, µ¿¸Æ, ¸ð¼¼Ç÷°ü¿¡ Á¸ÀçÇÏ´Â Ç÷ÀüÀÇ Ä¡·á¿¡ ÀÀ¿ëµË´Ï´Ù. ¶ÇÇÑ Æó »öÀüÁõ°ú ¸»ÃÊ µ¿¸Æ ÁúȯÀÇ Ä¡·á¿¡µµ »ç¿ëµË´Ï´Ù. ÇöÀç´Â ȯºÎ¿¡ µû¶ó ´Ù¸¥ Å©±â¿Í Á÷°æÀÇ °ÍÀÌ ³Î¸® ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù. dz¼± »öÀü¼ú, ¼ö¼ú »öÀü¼ú, ÈíÀÔ »öÀü¼ú µîÀÌ ÀÖ½À´Ï´Ù.
¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¸¸¼ºÁúȯÀº Àü ¼¼°è »ç¸Á°ú ½ÅüÀå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ù»Û ÀÏÁ¤, ¾É¾ÆÀÖ´Â ¶óÀÌÇÁ ½ºÅ¸ÀÏ, ÆÐ½ºÆ® Ǫµå ¼Òºñ·® Áõ°¡, Èí¿¬ÀÚ ¹× ¾ËÄÚ¿Ã ¼·ÃëÀÚ Áõ°¡ µîÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ Áúº´À¸·Î ÀÎÇÑ Áúº´·üÀº ÇöÀúÇÏ°Ô °¡¼Óȵǰí ÀÖ½À´Ï´Ù. À̰ÍÀº Ç÷Àü Á¦°Å ±â±â ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. °Ô´Ù°¡ ³ëÀÎ Àα¸ Áõ°¡, ³·Àº ħ½À(MI) ÀýÂ÷¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °¢±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó °³¼±µµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¼±µµÀûÀÎ Á¦Á¶¾÷ü´Â ±â¼úÀûÀ¸·Î ÷´Ü Ç÷Àü Á¦°Å ±â±â¸¦ µµÀÔÇϱâ À§ÇØ ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀåÀÇ ¹àÀº Àü¸ÁÀ» âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ À¯¸®ÇÑ ÀÇ·áºñ »óȯ°ú ¿µ»ó À¯µµ ¼ö¼úÀ» ¼öÇàÇÏ´Â ¿Ü°ú Àǻ簡 ÀÌ·¯ÇÑ ±â±â¸¦ ¼±È£ÇÏ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» °ÈÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global thrombectomy devices market size reached USD 1.41 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.13 Billion by 2033, exhibiting a growth rate (CAGR) of 4.48% during 2025-2033. The rising preference for thrombectomy devices by surgeons to perform image-guided surgeries and continuous improvements in healthcare infrastructures are primarily propelling the market.
Thrombectomy devices offer numerous benefits in surrogate endpoints, such as biomarker analysis, infarct size reduction, ST-segment resolution and angiographic thrombolysis in myocardial infarction (TIMI) flow. These devices minimize blood loss and damage caused to the vessel wall during a procedure. Consequently, they find application in treating blood clots present in veins, arteries and capillaries. They are also used to treat pulmonary embolism and peripheral arterial diseases. At present, they are widely available in different sizes and diameters, depending on the affected area. Some of the most frequently used thrombectomy devices procedures are balloon embolectomy, surgical embolectomy and aspiration embolectomy.
According to the World Health Organization (WHO), chronic diseases are the leading causes of death and disability around the world. Disease rates from these conditions are accelerating significantly on account of hectic schedules, sedentary lifestyles, rising consumption of fast food and the increasing number of individuals who smoke and consume alcohol. This represents one of the key factors propelling the growth of the thrombectomy devices market worldwide. Moreover, the growing geriatric population, along with the escalating demand for minimally invasive (MI) procedures and improving healthcare infrastructure in various countries, is also fueling the growth of the market. Furthermore, the leading manufacturers are increasing their investments in research and development (R&D) activities to introduce technologically advanced thrombectomy devices, which, in turn, is creating a positive outlook for the market. Besides this, favorable medical reimbursements and rising preference of these devices by surgeons for performing image-guided surgeries are anticipated to strengthen the market growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Argon Medical Devices Inc., Boston Scientific Corporation, Edwards Lifesciences Corporation, Johnson & Johnson, Medtronic Plc, Penumbra Inc., Spectranetics Corporation (Koninklijke Philips N.V.), Stryker Corporation, Teleflex Incorporated and Terumo Corporation.